0000950170-23-071113.txt : 20231218
0000950170-23-071113.hdr.sgml : 20231218
20231218163050
ACCESSION NUMBER: 0000950170-23-071113
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231214
FILED AS OF DATE: 20231218
DATE AS OF CHANGE: 20231218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goodman Vicki L
CENTRAL INDEX KEY: 0001901477
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41837
FILM NUMBER: 231494195
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mural Oncology plc
CENTRAL INDEX KEY: 0001971543
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
BUSINESS PHONE: 353 1 905 8020
MAIL ADDRESS:
STREET 1: 10 EARLSFORT TERRACE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 T380
FORMER COMPANY:
FORMER CONFORMED NAME: Mural Oncology Ltd
DATE OF NAME CHANGE: 20230403
FORMER COMPANY:
FORMER CONFORMED NAME: Pistachiovale Ltd
DATE OF NAME CHANGE: 20230329
4
1
ownership.xml
4
X0508
4
2023-12-14
0001971543
Mural Oncology plc
MURA
0001901477
Goodman Vicki L
C/O MURAL ONCOLOGY PLC
10 EARLSFORT TERRACE
DUBLIN 2
L2
D02 T380
IRELAND
false
true
false
false
Chief Medical Officer
false
Ordinary Shares
2023-12-14
4
A
false
73018
0.00
A
73018
D
Stock Option (right to buy)
3.61
2023-12-14
4
A
false
135604
0.00
A
2033-12-13
Ordinary Shares
135604
135604
D
Consists of ordinary shares issuable under 73,018 restricted stock units ("RSUs"). Each RSU represents the right to receive one ordinary share upon vesting. The RSUs are scheduled to vest with respect to 25% of the underlying ordinary shares on each of the first four anniversaries of November 6, 2023, subject to the reporting person's continued service with the Issuer.
This option was granted on December 14, 2023. The option is scheduled to vest with respect to 25% of the underlying ordinary shares on November 6, 2024 and the remaining 75% of the underlying ordinary shares shall vest in 12 equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer.
/s/ Maiken Keson-Brookes, attorney-in-fact for Vicki L. Goodman
2023-12-18